Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial Presenter: Dr. Martina Porter, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center Location: Hall A Date: Thursday, October 1, 2026 5:00pm CEST